CHMP issues further advice on thrombosis and thrombocytopenia with Vaxzevria (AstraZeneca ' s COVID-19 vaccine), EMA

Healthcare professionals are advised that Vaxzevria must not be administered to patients with thrombosis with thrombocytopenia syndrome after receiving the vaccine and patients should be monitored for thrombosis and thrombocytopenia within 3 weeks of vaccination.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news